| Literature DB >> 29215025 |
Qi Xiong1, Jianlin Chen1,2, Fei-Lin Li1, Shiji Zhao1, Xiaoping Wan1, Xiao Yang1, Jianglin Li3, Danyu Luo4, Zezhou Wang5, Xuebin Lv6, Rong Gao7.
Abstract
To develop a cost-effective molecular regulator to improve growth metabolism and immunity of animals, a recombinant plasmid co-expressing fatty acid desaturase (mFat-1) and pig insulin growth like factor 1 (IGF-1) genes was constructed by the 2 A self-cleavage technique. After entrapment within modified chitosan nanoparticles (chitosan modified with polyethyleneglycol-polyethylenimine, CPP), the recombinant plasmid was injected intramuscularly into mice. Compared with controls, co-expression of mFat-1 and IGF-1 significantly raised the level of serum IGF-1, and increased the liver and muscle docosa hexaenoic acid (DHA) content. Th and Tc cell levels were also elevated, as were expression levels of serum IL-4 and IL-6 genes. These results demonstrate that the immunity and metabolism of an animal can be effectively improved by co-expression of mFat-1 and IGF-1 genes in vivo, which may contribute to further development of novel immunomodulators with beneficial effects on growth metabolism and immunity.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29215025 PMCID: PMC5719438 DOI: 10.1038/s41598-017-17341-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Primers for Real-Time qPCR.
| Gene | Sequence(5′-3′) | Annealing Temperature (°C) |
|---|---|---|
| β-actin1 | F2: TACGCCAACACGGTGCTGTC | 58.0 |
| R3: GTACTCCTGCTTGCTGATCCACAT | ||
| IL-4 | F: GCTGCCCCAGAGAACACGAC | 61.0 |
| R: AGGTTCCTGTCAAGTCCGCTC | ||
| IL-6 | F: TGCAATGAGAAAGGAGATGTGTG | 56.5 |
| R: CCCAGATTGGAAGCATCCGT |
1The primer of β-actin is designed as reference gene. 2Forward primer. 3Reverse primer.
Figure 1Levels of IGF-1 in the sera of treated mice.
Figure 2DHA levels in different tissues of treated mice.
Figure 3TH and TC cells levels in the blood of treated mice.
Figure 4Immunoglobulins content in the sera of treated mice.
Figure 5Expression levels of IL-4 and IL-6 in the blood of treated mice.
Changes in mouse weights during the 4 weeks of observation (n = 10/group).
| Group | Initial weight (g) | End weight (g) | Net gain (g) | Average gain (g) |
|---|---|---|---|---|
| C | 25.3 ± 2.16 | 29.6 ± 2.14 | 4.3 ± 2.06 | 0.86a |
| A1 | 25.7 ± 3.27 | 31.8 ± 4.92 | 6.1 ± 3.21 | 1.22b |
| A2 | 25.3 ± 2.87 | 31.3 ± 3.38 | 6.0 ± 2.44 | 1.20b |
| A3 | 25.3 ± 2.54 | 32.4 ± 3.14 | 7.1 ± 2.76 | 1.42c |
Note: Different superscripts indicate significant differences (P < 0.05).